Estimation of Calcitonin Hormone Levels and its Relation with Tyrosine Kinase Enzyme in Thyroid Cancer Iraqi Patients
Keywords:
Thyroid cancer, Calcitonin hormone, Tyrosine kinase enzyme , Medullary thyroid cancer , Chemical treatmentAbstract
Medullary thyroid cancer accounts for 5% of all cases of thyroid cancer. It develops from the C-cells of the thyroid. Thus, in addition to its destructive impact on our health, cancer also significantly increases the overall healthcare burden. C-cells manufacture the hormone calcitonin, which plays a somewhat modest part in the process of bone development as well as blood calcium levels. That is because it holds the role of a poor substitute excreted if the thyroid is removed, the effect of calcitonin is weaker than that of thyroid hormone. Luckily, serum calcitonin concentrations that are higher than normal can help make a diagnosis and find out about a thyroid cancer recurrence. In contrast to almost all other thyroid type cancers, medullary thyroid cancer does not assimilate RAI and so the best way of saving the patient's life is to have the surgery done just in time when the tumour has not yet spread over the body. The greatest risk factor for medullary thyroid cancer is the occurrence of medullary thyroid cancer or MEN syndrome (multiple endocrine neoplasia syndromes) in families, up to 20% of cases carry a genetic flaw. Among other things, the patient screening for the eponymous mutation of the RET proto-oncogene should be given first priority. There are two forms of MEN syndrome. MEN 2A when the tumours develop in the medulla of the thyroid, adrenal and parathyroid glands. MEN 2B when it contains medullary thyroid carcinoma, pheochromocytoma, and multiple ganglioneuromas of the autonomic nervous system.
References
[1] Opsahl, E.M.; Lars, A.A.; Ellen, S.T.A.; et al. "Trends in diagnostics, surgical treatment, and prognostic factors for outcomes in medullary thyroid carcinoma in Norway: a nationwide population-based study,” Eur. Thyroid J., 8(1): 31–40, 2019.
[2] Hirsch, D.; Orit, T.; Sigal L.; Gideon, B.; Eyal, R.; David, J.G.; Haggi, M.; Carlos, B.; Simona, G.-G.; "Temporal trends in the presentation, treatment, and outcome of medullary thyroid carcinoma”. Thyroid, 28, 3, 369–376, 2018.
[3] Chen, D.W.; Brian, H.H.L.; Donald, S.A.; Kate, N.; Megan, R.H.; "Thyroid cancer." Lancet ,401, 10387 ,1531-1544, 2023.
[4] Rodríguez-Bel, L; Sabaté-Llobera, A; Rossi-Seoane, S; Reynés-Llompart, G; Vercher Conejero, J.L.; Cos-Domingo, M.; Moreno-Llorente, P.; et al.; “Diagnostic accuracy of 18F-FDG PET/CT in patients with biochemical evidence of recurrent, residual, or metastatic medullary thyroid carcinoma,” Clin. Nucl. Med., 44(3): 194–200, 2019.
[5] Weber, T.; “Medullary thyroid carcinoma: why is specialization mandatory?,” Visc. Med., 34(6): 419–421, 2018.
[6] Levitzki, A.; “Tyrosine kinases as targets for cancer therapy”. Eur. J. Cancer, 38: S11–S18, 2002.
[7] Tsiasioti, A.; Tzanavaras, P. D.; “Determination of glutathione and glutathione disulfide using zone fluidics and fluorimetric detection”. Talanta, 222, 121559, 2021.
[8] Buczinski, S.; Dubuc, J.; Bourgeois, V.; Baillargeon, P.; Côté, N.; Fecteau, G.; “Validation of serum gamma-glutamyl transferase activity and body weight information for identifying dairy calves that are too young to be transported to auction markets in Canada,” J. Dairy Sci., 103(3): 2567–2577, 2020.
[9] Silvestre, C.; Joaquim, S.; Matias, H. P.; Maria, J. B.; "Calcitonin screening in nodular thyroid disease: is there a definitive answer?." Eur. Thyroid J. ,8: 79-82 ,2019.
[10] Xin, N. I. E.; Yong, H. E.; Meng-ting, Y. I. N.; Gui-xing, L. I.; "Value of Baseline Calcitonin for Differential Diagnosis of Medullary Thyroid Cancer". J. Sichuan Univ. (Med. Sci.) 54(2), 432-438, 2023.
[11] Borget, I.; De Pouvourville, G.; Schlumberger, M.; “Calcitonin determination in patients with nodular thyroid disease”. J. Clin. Endocrinol. Metab., 92(2): 425–427, 2007.
[12] Fallahi, P.; Silvia M. F.; Maria, R. G.; Gilda, V. G. E.; Francesca, R.; Sabrina, R. P.; Salvatore B.; Alessandro, A.; "Molecular targets of tyrosine kinase inhibitors in thyroid cancer. Semin. Cancer Biol., 79: 180-196, 2022.
[13] Puliafito, I.; Francesca, E.; Angela, P.; Stefania, M.; Dorotea, S.; Maria P. V.; Dario, G.; "Target therapy in thyroid cancer: current challenge in clinical use of tyrosine kinase inhibitors and management of side effects". Front. Endocrinol. 8(13): 860671, 2022.
[14] Ezabella, M. C.; et al.; “Early detection of medullary thyroid carcinoma in multiple endocrine neoplasia type II”. Rev. Hosp. Clin. Fac. Med. Sao. Paulo., 45(3): 105–109, 1990.
[15] Wang, Z.; et al., “Tyrosine kinase inhibitor–induced hypothyroidism: mechanism and clinical implications”. Eur. J. Clin. Pharmacol., 80(6): 827–838, 2024.
[16] Demlová, R.; Turjap, M.; Peš, O.; Kostolanská, K.; Jurica, .; “Therapeutic drug monitoring of sunitinib in gastrointestinal stromal tumors and metastatic renal cell carcinoma in adults—a review”. Ther. Drug Monit., 42(1): 20–32, 2020.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 May R. Abdul Hamza, Firas A. Hassan
This work is licensed under a Creative Commons Attribution 4.0 International License.
.jpg)
